RT Journal
A1 Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R
T1 REactivation of retinopathy of prematurity after bevacizumab injection
JF Archives of Ophthalmology
JO Archives of Ophthalmology
YR 2012
FD August 1
VO 130
IS 8
SP 1000
OP 1006
DO 10.1001/archophthalmol.2012.592
UL http://dx.doi.org/10.1001/archophthalmol.2012.592
AB Objective 
                  To report late reactivation and progression of retinopathy of prematurity (ROP) after intravitreal bevacizumab monotherapy.Methods 
                  Retrospective review of 9 patients (17 eyes) with recurrence of ROP after initial treatment with intravitreal bevacizumab monotherapy. Data collected included (1) location and stage of ROP activity, (2) number and timing of treatments, and (3) structural outcomes.Results 
                  Mean age at treatment-requiring recurrence was 49.3 weeks (SD, 9.1 weeks; minimum, 37 weeks; maximum, 69 weeks) postmenstrual age (PMA). The mean time between initial treatment and treatment-requiring recurrence was 14.4 weeks, with a minimum of 4 and maximum of 35 weeks. Fives eyes progressed to retinal detachment (4 eyes stage 5, 1 eye stage 4a). Age at retinal detachment ranged from 49 to 69 weeks PMA with a median of 55 weeks PMA and mean of 58.4 weeks PMA. No eye that received laser treatment for recurrence progressed to retinal detachment.Conclusions 
                  Although intravitreal bevacizumab treatment is effective in inducing regression of ROP, the effect may be transient. Recurrence can occur later in the course than with conventional laser therapy. Late retinal detachment can occur despite early regression. Long-term favorable structural outcome may require extended observation and retreatment. Laser may be a useful treatment for recurrences.